JP2023519446A5 - - Google Patents
Info
- Publication number
- JP2023519446A5 JP2023519446A5 JP2023502029A JP2023502029A JP2023519446A5 JP 2023519446 A5 JP2023519446 A5 JP 2023519446A5 JP 2023502029 A JP2023502029 A JP 2023502029A JP 2023502029 A JP2023502029 A JP 2023502029A JP 2023519446 A5 JP2023519446 A5 JP 2023519446A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- aib
- ser
- gly
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994716P | 2020-03-25 | 2020-03-25 | |
| US62/994,716 | 2020-03-25 | ||
| PCT/JP2021/014423 WO2021193984A2 (en) | 2020-03-25 | 2021-03-25 | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519446A JP2023519446A (ja) | 2023-05-10 |
| JP2023519446A5 true JP2023519446A5 (enExample) | 2024-04-04 |
Family
ID=76502784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502029A Pending JP2023519446A (ja) | 2020-03-25 | 2021-03-25 | Ｇｉｐ受容体アゴニストペプチド化合物のｑｄ投薬及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220227830A1 (enExample) |
| EP (1) | EP4126921A2 (enExample) |
| JP (1) | JP2023519446A (enExample) |
| KR (1) | KR20230005184A (enExample) |
| CN (1) | CN115335395A (enExample) |
| AR (1) | AR121650A1 (enExample) |
| AU (1) | AU2021241257A1 (enExample) |
| BR (1) | BR112022019114A2 (enExample) |
| CA (1) | CA3173129A1 (enExample) |
| CL (1) | CL2022002598A1 (enExample) |
| CO (1) | CO2022014959A2 (enExample) |
| EC (1) | ECSP22074680A (enExample) |
| IL (1) | IL296592A (enExample) |
| MX (1) | MX2022011816A (enExample) |
| PE (1) | PE20230107A1 (enExample) |
| PH (1) | PH12022552562A1 (enExample) |
| TW (1) | TW202202516A (enExample) |
| WO (1) | WO2021193984A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| IL296219A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
| CN118754965A (zh) | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
| WO2023139106A2 (en) * | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| CA2597649A1 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| US8497240B2 (en) * | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| CA2872314C (en) * | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| DK3004155T3 (da) * | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| JOP20190211A1 (ar) * | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
-
2021
- 2021-03-25 IL IL296592A patent/IL296592A/en unknown
- 2021-03-25 JP JP2023502029A patent/JP2023519446A/ja active Pending
- 2021-03-25 KR KR1020227037256A patent/KR20230005184A/ko not_active Ceased
- 2021-03-25 MX MX2022011816A patent/MX2022011816A/es unknown
- 2021-03-25 BR BR112022019114A patent/BR112022019114A2/pt unknown
- 2021-03-25 AR ARP210100730A patent/AR121650A1/es unknown
- 2021-03-25 WO PCT/JP2021/014423 patent/WO2021193984A2/en not_active Ceased
- 2021-03-25 CN CN202180023814.5A patent/CN115335395A/zh active Pending
- 2021-03-25 EP EP21733232.9A patent/EP4126921A2/en active Pending
- 2021-03-25 TW TW110110874A patent/TW202202516A/zh unknown
- 2021-03-25 AU AU2021241257A patent/AU2021241257A1/en active Pending
- 2021-03-25 PH PH1/2022/552562A patent/PH12022552562A1/en unknown
- 2021-03-25 PE PE2022002094A patent/PE20230107A1/es unknown
- 2021-03-25 CA CA3173129A patent/CA3173129A1/en active Pending
- 2021-12-17 US US17/554,539 patent/US20220227830A1/en not_active Abandoned
-
2022
- 2022-09-23 CL CL2022002598A patent/CL2022002598A1/es unknown
- 2022-09-23 EC ECSENADI202274680A patent/ECSP22074680A/es unknown
- 2022-10-20 CO CONC2022/0014959A patent/CO2022014959A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500483A5 (enExample) | ||
| JP2023524603A5 (enExample) | ||
| JP2023012547A5 (enExample) | ||
| JP6814891B2 (ja) | ベンズイミダゾール誘導体の酸付加塩 | |
| TW200840571A (en) | Piperidine derivatives and methods of use thereof | |
| IL269581B1 (en) | GIP receptor activating peptide | |
| JP7769695B2 (ja) | Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 | |
| ES2460919T3 (es) | Formas polimórficas de p-hidroxibenzoato de (2S)-(4E)-N-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amonio para el tratamiento de trastornos del sistema nervioso central | |
| MX2011010448A (es) | Profarmacos de opioides novedosos de amino acidos y peptidos enlazados a acido dicarboxilico y usos de los mismos. | |
| JP2010502714A (ja) | 乾燥粉末の化合物の処方物およびその使用 | |
| US12084431B2 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| CN101426500A (zh) | 治疗糖尿病和肥胖症的二肽基肽酶iv抑制剂和cb1受体拮抗剂的药物组合物 | |
| CN102046201B (zh) | 镇痛耐受性抑制剂 | |
| CA3133768A1 (en) | Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia | |
| TW202227455A (zh) | 異喹啉衍生物的無定形形式 | |
| KR101858881B1 (ko) | 4-｛4-[(1e)-4-(2,9-디아자스피로[5.5]운데스-2-일)부트-1-엔-1-일]-2-메틸벤질｝-5-(프로판-2-일)-1h-피라졸-3-일 베타-d-글루코피라노시드 아세테이트 | |
| US10787456B2 (en) | Opioid antagonists and methods related thereto | |
| TWI374880B (en) | A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof | |
| KR20220061184A (ko) | 니코티닐 알코올 에테르 유도체의 말레에이트, 이의 결정형, 및 이의 응용 | |
| CN101496802B (zh) | 芳基哌嗪衍生物在制备治疗疼痛药物方面的用途 | |
| EP1871364A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| WO2010050422A1 (ja) | 糖尿病治療剤 | |
| US20220185767A1 (en) | Novel ternary molecular complex of tamibarotene for cancer stem cells treatment | |
| CN104470361A (zh) | 利用基于磷脂酰胆碱的制剂增加口服甲基纳曲酮的生物利用度 | |
| CN114616224A (zh) | 新型三环5-ht2拮抗剂 |